Implementation of three-dimensional (3D) cell culture nanofiber systems in industrial vaccine production offers much higher viral vaccine titers, greater scalability and improved process economy, but it will require tight collaboration with the industry to help speed up their wide adoption, stresses Laura Chirica from Cellevate.  

As geopolitical factors are driving a greater focus on U.S. manufacturing, many companies are seeking ways to improve productivity while keeping their products affordable for patients, highlights Russel Miller from Enzene.

Innovation is driving OSD into new frontiers, from orally delivered biologics and enhanced solubility to sustainable manufacturing and AI-driven formulation development, asserts Shahrzad Missaghi from Colorcon.

For Timothy Compton from Alcami, there are numerous trends driving the surge in demand for U.S. based bio/pharma manufacturing, including the benefits of a greater quality culture and adaptability to batch size requirements.

CDMOs need to be more than just providers of capacity, they need to be integrated strategic solution partners, embedding flexibility, reliability, and sustainability into their business models, according to Dr. Max Lauwiner from Valsynthese.

Having a partner involved from the outset of a sterile fill/finish project to help plan and support at each stage, is a potentially beneficial approach for innovators, highlights Hanns-Christian Mahler from ten23 health.

Increasingly complex and moisture-sensitive ingredients require careful, considered, and connected approaches that ensure the integrity of the finished product is maintained, explains Christian Classen from Sanner Group.

This year’s show, taking place in Frankfurt, Germany, has grown further incorporating representation from the whole bio/pharma supply chain and providing networking opportunities for a global audience, reveals Tara Dougal, Event Director.

According to Kevin Li from BioDuro, bio/pharma partnerships are most successful when the parties involved are aligned, operating as one team with mutual trust and long-term vision.

It is possible to achieve longer-acting injectable drug products that also do not require aseptic fill/finish thanks to a new advanced drug delivery system, reveals Mårten Rooth from Nanexa.

While widespread adoption of 3D printing within the bio/pharma industry needs to overcome some key hurdles, its potential for the future is tremendous, emphasizes Tom Sellig from Adare Pharma Solutions.

Bio/pharma companies are turning their focus to Indian CDMOs to build resilience into their KSM and API supply chains and to help with complex payloads, according to Yann D’Hervé from Cohance.

Bio/pharma companies are adjusting their strategies to cope with a variety of industry trends and are seeking out partners that can not only provide them with capacity but also support them through their innovation journey.

As demand for increasingly complex biologics grows, technological advances and innovative approaches are enabling companies to progress their biomanufacturing efforts.

With an increasing spotlight on sustainability, it is increasingly important for industry-wide sustainability practices to be implemented to ensure transformative change is achieved.

While biomanufacturing has ample capacity, a funding downturn and workforce shortages have created a paradoxical situation, putting pressure on sponsors’ decisions when it comes to choosing their manufacturing partners.

While there have been promising advances in terms of technologies to help the development and manufacture of next-gen therapies, limitations remain; but, it is likely that AI will be revolutionary for development in the near future.

Advanced technologies, while important for the successful development and manufacture of next-gen therapies, are still a long way off being impactful, meaning more investment is needed to reap the rewards of these promising treatments.

Digital systems, automation, and flexibility are crucial for overcoming the hurdles associated with the development and manufacture of next-gen therapies, but ongoing investment is critical to ensure continued innovation in the sector.

Affordability and accessibility are critical factors for commercial success of next-gen therapies; however, greater industry collaboration is needed to reduce inefficiencies in the development of advanced technologies.